Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outcomes-Based Contracts Aren’t So Easy, Harvard Pilgrim Cautions

This article was originally published in The Pink Sheet Daily

Executive Summary

Value-based, risk-sharing reimbursement contracts were a hot topic at ISPOR, but Harvard Pilgrim Health Care Chief Medical Officer Michael Sherman cautioned that finding the right drug and the right pharma partner to work with are challenging.

You may also be interested in...



Pricing Pressure On Drugs To Intensify As Some Enrollee Cost-Shifting Measures Plateau – PwC

Employers’ may also look more at pitting their health plan vendors against each other for cost-saving coverage, meaning drug makers face more pressure to negotiate reimbursement and other new approaches with health plans, a PwC report suggests.

Brilinta/Bydureon’s Measurable Outcomes Are Smooth Fit For Contracts

Three-year contracts between AstraZeneca and Harvard Pilgrim focus on reduced hospitalization for Brilinta, reaching HbA1c goals for Bydureon; choosing appropriate products and outcomes are key challenge for the new reimbursement approaches.

AstraZeneca's 13 Outcomes-Based Contracts Show “Proactive" Engagement On New Models

AstraZeneca VP-Market Access Rick Suarez talks about challenges and opportunities in the emerging area of innovative outcomes-based reimbursement contracts, and specifically two new contracts with Harvard Pilgrim for Bydureon and Brilinta.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS079527

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel